派格生物医药-B(02565)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

02565 派格生物医药-B

已收盘 06-17 16:08:37

6.200

-0.210

-3.28%

最高6.460	最低6.100	成交量1,035万
今开6.450	昨收6.410	日振幅5.62%
总市值24.24亿	流通市值17.61亿	总股本3.91亿
成交额6,488万	换手率3.64%	流通股本2.84亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"02565","market":"HK","secType":"STK","nameCN":"派格生物医药-B","latestPrice":6.2,"timestamp":1781683717006,"preClose":6.41,"halted":0,"volume":10349550,"delay":0,"changeRate":-0.03276131045241809,"floatShares":284000000,"shares":391000000,"eps":-0.55,"marketStatus":"已收盘","change":-0.21,"latestTime":"06-17 16:08:37","open":6.45,"high":6.46,"low":6.1,"amount":64883955,"amplitude":0.056162,"askPrice":6.21,"askSize":4400,"bidPrice":6.2,"bidSize":91900,"shortable":3,"etf":0,"ttmEps":-0.612785,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1781746200000},"marketStatusCode":5,"adr":0,"listingDate":1748275200000,"exchange":"SEHK","adjPreClose":6.41,"openAndCloseTimeList":[[1781659800000,1781668800000],[1781672400000,1781683200000]],"volumeRatio":0.910373,"lotSize":50,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02565/tweets","defaultTab":"tweets","newsList":[{"id":"1180055525","title":"异动解读｜派格生物医药-B盘中下跌8.23%，诉讼风险叠加行业弱势持续承压","url":"https://stock-news.laohu8.com/highlight/detail?id=1180055525","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1180055525?lang=zh_cn&edition=full","pubTime":"2026-06-16 11:46","pubTimestamp":1781581564,"startTime":"0","endTime":"0","summary":"6月16日，派格生物医药-B盘中下跌8.23%，报6.47港元/股，成交额3493.59万港元，股价再创52周新低。此外，公司自上市以来股价已从高位大幅回落，近3个月累计跌幅超过85%，市场情绪持续低迷。行业层面，生物科技板块整体走弱，康方生物跌6.21%、三生制药跌5.03%、信达生物跌1.81%，板块联动效应进一步加剧抛压。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02565"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1104416364","title":"异动解读｜派格生物医药-B盘中上涨8.37%，收到腾瑞制药商业化首笔权益金6100万港元提振信心","url":"https://stock-news.laohu8.com/highlight/detail?id=1104416364","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1104416364?lang=zh_cn&edition=full","pubTime":"2026-06-08 10:22","pubTimestamp":1780885322,"startTime":"0","endTime":"0","summary":"6月8日，派格生物医药-B盘中上涨8.37%，报8.4港元/股，成交额9318.64万港元。消息面上，公司6月5日晚间公告，已收到上海腾瑞制药支付的维培那肽注射液（派达康）在中国大陆地区商业化合作首笔权益金6100万港元，标志着双方合作进入实质履约及全面推进阶段。此外，近期公司CR059研究成果入选EASD口头发言环节、董事会提议回购不超过10%已发行H股、核心产品纳入医保参照药预沟通增补公示等多重利好共振，持续推动股价反弹。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02565"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641720791","title":"港股异动 | 派格生物医药-B(02565)涨超6% 收到腾瑞制药维培那肽商业化首笔权益金6100万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2641720791","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2641720791?lang=zh_cn&edition=full","pubTime":"2026-06-08 09:34","pubTimestamp":1780882478,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，派格生物医药-B涨超6%，截至发稿，涨5.38%，报8.43港元，成交额3147.58万港元。消息面上，6月5日晚，派格生物发布自愿公告，公司已收到上海腾瑞制药支付的首笔商业化合作权益金港币6100万元。公告显示，该笔款项来自双方此前围绕派格生物自主研发的国家1类新药维培那肽注射液派达康在中国大陆地区商业化推广达成的合作安排。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1451200.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["XBI","BK4581","BK4585","02565","01477","BK4588","BK1574","BK1191","VXUS","399441","161726","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641316114","title":"派格生物医药-B(02565)收到腾瑞制药维培那肽商业化首笔权益金6100万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2641316114","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2641316114?lang=zh_cn&edition=full","pubTime":"2026-06-05 18:08","pubTimestamp":1780654114,"startTime":"0","endTime":"0","summary":"智通财经APP讯，派格生物医药-B 发布公告，就有关本集团与上海腾瑞制药股份有限公司就本集团自主研发的国家1类新药维培那肽注射液(派达康)在中国大陆地区商业化推广达成合作安排。根据双方已签署的商业化合作协议，本集团已收到腾瑞制药支付的首笔权益金6100万港元。派达康为本集团自主研发并已获国家药品监督管理局批准上市的长效GLP-1受体激动剂，用于2型糖尿病治疗。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1450802.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4585","161726","XBI","BK1191","399441","BK1161","02565","BK1574","BK4581","BK4588","01477"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1109583007","title":"异动解读｜派格生物医药-B盘中上涨8.52%，多重利好共振延续反弹势头","url":"https://stock-news.laohu8.com/highlight/detail?id=1109583007","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1109583007?lang=zh_cn&edition=full","pubTime":"2026-06-04 13:42","pubTimestamp":1780551720,"startTime":"0","endTime":"0","summary":"6月4日，派格生物医药-B盘中上涨8.52%，报8.79港元/股，成交额1.38亿港元。消息面上，公司近期连续释放多重利好。此外，核心产品维培那肽注射液已纳入医保参照药预沟通增补公示，医保准入预期持续强化。多重利好叠加前期解禁抛压释放充分，推动股价延续反弹。派格生物医药是一家深耕慢病代谢领域的生物科技公司，核心产品为长效GLP-1受体激动剂，主要用于治疗2型糖尿病及肥胖症等代谢疾病。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"ef940962f0c477eadc718e7ed8810673","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02565"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1150523805","title":"派格生物医药-B更新2026年5月股份变动月报表，股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1150523805","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1150523805?lang=zh_cn&edition=full","pubTime":"2026-06-03 16:46","pubTimestamp":1780476394,"startTime":"0","endTime":"0","summary":"2026年6月3日，派格生物医药（杭州）股份有限公司公布2026年5月的证券变动月报表。本次报告期为截至2026年5月31日止的一个月，显示公司注册股本及已发行股份总数均未发生变化。截至5月31日，公司H股已发行股份数量为284,300,339股，非上市股份数量为106,791,193股，注册股本合计为391,091,532股。公司进一步确认，上市股份部分的公众持股比例符合香港联交所要求。截至报告期末，公司股本总数保持稳定。公告由联席公司秘书黄一峰签署。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02565"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640967369","title":"港股异动 | 派格生物医药-B(02565)涨超13% CR059获EASD 2026接收并入选口头讨论发言环节","url":"https://stock-news.laohu8.com/highlight/detail?id=2640967369","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640967369?lang=zh_cn&edition=full","pubTime":"2026-06-02 10:06","pubTimestamp":1780365980,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，派格生物医药-B涨超13%，截至发稿，涨9.8%，报8.75港元，成交额1.08亿港元。消息面上，6月1日，派格生物医药-B发布公告，集团自主研发的环状RNA编码GLP-1类似物CR059研究成果已获第62届欧洲糖尿病研究协会年会接收，并入选口头讨论发言环节。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1448904.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","161726","02565","BK4588","399441","VXUS","XBI","BK4585","BK4581"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1161952653","title":"异动解读｜派格生物医药-B盘中上涨10.55%，CR059入选EASD口头发言叠加回购计划提振信心","url":"https://stock-news.laohu8.com/highlight/detail?id=1161952653","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1161952653?lang=zh_cn&edition=full","pubTime":"2026-06-02 10:05","pubTimestamp":1780365902,"startTime":"0","endTime":"0","summary":"6月2日，派格生物医药-B盘中上涨10.55%，报8.72港元/股，成交额1.08亿港元。消息面上，公司近日连续释放多重利好。另一方面，公司董事会提议授予一般性授权，允许回购不超过已发行H股总数10%的股份，将于6月24日股东大会审议。此外，公司核心产品维培那肽注射液此前已纳入医保参照药预沟通增补公示，医保准入预期持续强化。多重利好共振推动股价走强。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02565"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1137707353","title":"派格生物医药-B拟回购最多10%股份","url":"https://stock-news.laohu8.com/highlight/detail?id=1137707353","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1137707353?lang=zh_cn&edition=full","pubTime":"2026-06-01 22:16","pubTimestamp":1780323410,"startTime":"0","endTime":"0","summary":"派格生物医药(杭州)股份有限公司公告称，董事会已提议授予一般性授权，允许回购不超过相关决议案获得批准当日已发行H股总数10%的股份。该公司在香港联交所主要上市，将于2026年6月24日召开股东周年大会审议该授权。公司提醒股东注意，自2026年6月18日至2026年6月24日暂停办理股份过户，届时名列股东名册者可参与大会投票。该授权最终能否生效及其具体实施计划，将取决于当日股东大会的表决结果。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"派格生物医药-B拟回购最多10%股份","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02565"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638642026","title":"派格生物医药-B(02565)：维培那肽注射液纳入2026年第二批参照药预沟通增补药品信息公示","url":"https://stock-news.laohu8.com/highlight/detail?id=2638642026","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2638642026?lang=zh_cn&edition=full","pubTime":"2026-05-28 18:18","pubTimestamp":1779963488,"startTime":"0","endTime":"0","summary":"智通财经APP讯，派格生物医药-B 发布公告，根据国家医疗保障局于2026年5月27日发布的《关于2026年第二批参照药预沟通增补药品信息的公示》，本公司申报的维培那肽注射液相关材料经反馈后已被确认符合2026年第二批参照药预沟通的申报要求，并已纳入本次增补药品信息公示范围。本次进入增补公示范围，标志着维培那肽注射液在国家医保参照药预沟通相关工作中取得阶段性进展，有助于后续参照药确认、医保准入及支付管理相关工作的有序推进。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1447239.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4581","BK1161","BK4585","161726","XBI","BK4588","399441","02565"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1140836570","title":"异动解读 | 派格生物医药-B盘中大涨5.33%，超跌反弹成主因","url":"https://stock-news.laohu8.com/highlight/detail?id=1140836570","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1140836570?lang=zh_cn&edition=full","pubTime":"2026-05-28 09:33","pubTimestamp":1779931980,"startTime":"0","endTime":"0","summary":"派格生物医药-B今日盘中大涨5.33%，引起了市场的广泛关注。消息面上，该股昨日因上市满一周年，IPO前股东所持股份禁售期全面到期，大量低成本筹码集中解禁，导致股价出现急跌。经历昨日重挫后，今日股价出现技术性超跌反弹。派格生物医药是一家深耕慢病代谢领域的生物科技公司，核心产品为接近商业化阶段的长效GLP-1受体激动剂PB-119，主要用于治疗2型糖尿病及肥胖症等代谢疾病。","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["02565"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1184530545","title":"异动解读｜派格生物医药-B盘中上涨10.77%，解禁抛压集中释放后技术性反弹","url":"https://stock-news.laohu8.com/highlight/detail?id=1184530545","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1184530545?lang=zh_cn&edition=full","pubTime":"2026-05-28 09:31","pubTimestamp":1779931884,"startTime":"0","endTime":"0","summary":"5月28日，派格生物医药-B盘中上涨10.77%，报9.71港元/股，成交额365.18万港元。消息面上，该股昨日恰逢上市满一周年，IPO前股东所持股份禁售期全面到期，大量低成本筹码集中解禁，盘中一度重挫逾15%，股价最低触及8.78港元。派格生物医药是一家深耕慢病代谢领域的生物科技公司，核心产品为接近商业化阶段的长效GLP-1受体激动剂PB-119，主要用于治疗2型糖尿病及肥胖症等代谢疾病。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02565"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1116027974","title":"异动解读｜派格生物医药-B盘中下跌15.99%，上市满周年禁售期全面解禁引发抛压","url":"https://stock-news.laohu8.com/highlight/detail?id=1116027974","media":"行情直击","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1116027974?lang=zh_cn&edition=full","pubTime":"2026-05-27 09:39","pubTimestamp":1779845942,"startTime":"0","endTime":"0","summary":"5月27日，派格生物医药-B盘中下跌15.99%，报9.29港元/股，成交额4687.47万港元。消息面上，派格生物医药-B于去年5月27日在港交所挂牌上市，今日恰逢上市满一周年，IPO前股东所持股份禁售期全面到期，大量低成本筹码集中解禁。派格生物医药是一家深耕慢病代谢领域的生物科技公司，核心产品为接近商业化阶段的长效GLP-1受体激动剂PB-119，主要用于治疗2型糖尿病及肥胖症等代谢疾病。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02565"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638534935","title":"格隆汇个股放量排行榜 | 5月25日","url":"https://stock-news.laohu8.com/highlight/detail?id=2638534935","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2638534935?lang=zh_cn&edition=full","pubTime":"2026-05-25 17:30","pubTimestamp":1779701404,"startTime":"0","endTime":"0","summary":"股票名称成交额（万）量比持续放量天数天利控股集团26177.222.493百富环球2703.382.425中联发展控股1067.482.361优必选217973.061.981华润医疗1719.231.911滔搏3529.591.832胜宏科技350159.461.791数码通电讯961.431.781九龙仓集团17387.851.641蔚来-SW46990.051.551高鑫零售1589.461.521科伦博泰生物60133.001.496九福来102.461.451中集集团7903.471.441北大青鸟环宇360.511.371PACIFIC LEGEND740.851.361中海油田服务9347.601.361MOS HOUSE695.301.331百果园集团641.011.291中芯国际1651388.781.282量化派3423.981.231佰泽医疗5107.781.191时代天使8886.501.192五一视界215348.591.182稀美资源-五百6200.381.1710电讯盈科6323.451.171美格智能7545.751.171深圳高速公路股份1185.201.172森松国际19247.321.143兖矿能源47039.851.111大象未来集团855.821.091通通AI社交2016.021.061兆易创新243","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2026/05/25173057187788.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["01919","00199","02050","06990","09926","02565","06681","09869","06603","08547","02418","02259","06110","01211","00152","00004","09866","02172","01516","02598","00087","00909","02506","00107","00981","02142","06699","00384","02609","00165","06613","00177","03888","01672","02291","02685","00117","00008","01473","06955","03986","09626","09993","02155","02587","00081","01477","02714","09880","01592"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2636855893","title":"派格生物医药-B(02565)提名廖亦琳为独立非执行董事候选人","url":"https://stock-news.laohu8.com/highlight/detail?id=2636855893","media":"智通财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636855893?lang=zh_cn&edition=full","pubTime":"2026-05-19 19:44","pubTimestamp":1779191040,"startTime":"0","endTime":"0","summary":"于2026年5月19日，董事会已审议并批准相关决议案，提名廖亦琳女士为公司第二届董事会独立非执行董事候选人。廖亦琳女士的任期将自公司股东大会批准当日起至第二届董事会任期届满时止。待廖亦琳女士于股东大会上获选为独立非执行董事后，廖亦琳女士将接替范新鹏女士担任审计委员会主席以及薪酬与考核委员会及提名委员会各自的成员，任期与其担任第二届董事会独立非执行董事的任期一致。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1443578.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4581","161726","BK4585","BK1161","399441","BK4588","XBI","02565"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636302846","title":"港股异动 | 派格生物医药-B(02565)尾盘飙升150% 此前与腾瑞制药达成派达康中国大陆独家商业化合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2636302846","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636302846?lang=zh_cn&edition=full","pubTime":"2026-05-18 15:43","pubTimestamp":1779090229,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，派格生物医药-B(02565)尾盘飙升150%，截至发稿，涨106.97%，报23.16港元，成交额7.84亿港元。消息面上，派格生物医药今年3月公布，与腾瑞制药就派达康在中国大陆地区的商业化合作签署战略合作协议。双方在合作协议中确立以实现累计销售规模超过人民币100亿元作为核心商业化目标。根据合作协议，腾瑞制药将向公司支付合计约1.4亿港币的权益金。值得注意的是，5月12日，方舟健客与腾瑞制药举行战略合作签约仪式。本次战略签约后，备受瞩目的创新GLP-1类药物派达康（维培那肽注射液）将于近期在方舟健客互联网医院平台全网首发。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1442854.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4588","161726","XBI","BK1191","VXUS","BK4581","BK1574","399441","01477","02565","BK4585","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636304327","title":"“2026智通财经夏季路演大会”活动报名中 ！","url":"https://stock-news.laohu8.com/highlight/detail?id=2636304327","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636304327?lang=zh_cn&edition=full","pubTime":"2026-05-18 10:06","pubTimestamp":1779069961,"startTime":"0","endTime":"0","summary":"5月28日，深圳前海。40+港股上市公司集中路演，与机构及高净值投资者面对面交流。","market":"us","thumbnail":"https://img.zhitongcaijing.com/image/20260518/20260518102433_43763.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/image/20260518/20260518102433_43763.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1442727.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["02623","01021","03858","BK1171","01333","00363","02675","HK0001040143.USD","02411","01300","02655","02729","00650","00826","02575","06090","03317","03881","08299","02726","01907","02706","00400","BK1100","00290","02526","BK1155","LU0307460666.USD","02652","09696","06682","02889","00305","02685","06651","01384","06938","02228","02142","06636","LU0314109678.HKD","02670","01396","VXUS","01378","02659","02650","06051","LU0287142896.SGD","02565"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1127496308","title":"派格生物医药-B2026年4月股份维持稳定 无新增发行或回购","url":"https://stock-news.laohu8.com/highlight/detail?id=1127496308","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1127496308?lang=zh_cn&edition=full","pubTime":"2026-05-06 16:48","pubTimestamp":1778057312,"startTime":"0","endTime":"0","summary":"派格生物医药（杭州）股份有限公司于2026年5月6日发布了截至2026年4月30日的月度证券变动报告。报告显示，公司本月未进行新增发行、购回、注销或库藏股变动，股本结构保持稳定。根据公告，普通股H股的已发行股数月末结存为284,300,339股，与上月相同。注册股本合计为人民币391,091,532元，与上月保持一致。截至4月底，H股公众持股比例符合港交所上市规则要求。公司表示，将继续严格遵守香港联合交易所有限公司上市规则及相关法律法规的各项要求。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"8d4c202617d87be1d9fe31f833a300a8","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02565"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1119189720","title":"异动解读 | 基石投资者延长禁售期彰显信心，派格生物医药-B盘中大涨近19%","url":"https://stock-news.laohu8.com/highlight/detail?id=1119189720","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1119189720?lang=zh_cn&edition=full","pubTime":"2026-05-05 16:17","pubTimestamp":1777969049,"startTime":"0","endTime":"0","summary":"派格生物医药-B今日盘中大幅上涨，涨幅一度达到18.91%，表现异常强劲。消息面上，此次股价异动与公司近期公布的一则消息密切相关。派格生物医药宣布，其基石投资者已同意自愿延长禁售期，在原定期满日后，直至5月20日期间不会以任何方式减持所持股份。分析指出，派格生物医药是国内少数能够实现药用聚乙二醇原料自主生产，并将其整合应用于慢性疾病药物全流程开发的企业。","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["02565"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633990288","title":"港股异动 | 派格生物医药-B(02565)最高涨近19% 公司深耕慢病代谢领域 延长禁售期彰显长期信心","url":"https://stock-news.laohu8.com/highlight/detail?id=2633990288","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2633990288?lang=zh_cn&edition=full","pubTime":"2026-05-05 16:03","pubTimestamp":1777968239,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，派格生物医药-B今日走势强劲，盘中最高涨18.91%，报29.3港元，成交额达5965.98万港元。消息面上，派格生物医药近期公布，基石投资者同意自愿禁售期届满日起至5月20日不会以任何方式减持任何持股。公司认为，禁售延长表明基石投资者基于公司对推进技术方面的研发能力及在重大临床里程碑方面取得的重大进展，对公司的未来前景充满信心。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1438070.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4588","XBI","399441","02565","VXUS","BK4581","161726","BK4585","BK1161"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.pegbio.com","stockEarnings":[{"period":"1week","weight":-0.1865},{"period":"1month","weight":-0.4272},{"period":"3month","weight":-0.886},{"period":"6month","weight":-0.8994},{"period":"1year","weight":-0.3033},{"period":"ytd","weight":-0.9071}],"compareEarnings":[{"period":"1week","weight":-0.0029},{"period":"1month","weight":-0.0566},{"period":"3month","weight":-0.0588},{"period":"6month","weight":-0.0394},{"period":"1year","weight":0.018},{"period":"ytd","weight":-0.0443}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"派格生物医药（杭州）股份有限公司是一家主要从事研究及开发慢性病创新疗法的中国公司。该公司的主要产品PB-119是自主开发、接近商业化阶段的长效胰高血糖素样肽1（GLP-1，一种降低血糖水平的肽类激素）受体激动剂。该公司的候选产品包括PB-718、PB-1902、PB-722、PB-2301和PB-2309。该公司的产品主要用于治疗2型糖尿病（T2DM）、肥胖症、非酒精性脂肪性肝炎（NASH）、阿片类药物引起的便秘（OIC，使用阿片类药物引起的胃肠道疾病）及先天性高胰岛素血症（一种罕见的内分泌疾病，患者持续出现低血糖症）等常见慢病及代谢疾病。","exchange":"SEHK","name":"派格生物医药-B","nameEN":"PEGBIO CO-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"派格生物医药-B(02565)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供派格生物医药-B(02565)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"派格生物医药-B,02565,派格生物医药-B股票,派格生物医药-B股票老虎,派格生物医药-B股票老虎国际,派格生物医药-B行情,派格生物医药-B股票行情,派格生物医药-B股价,派格生物医药-B股市,派格生物医药-B股票价格,派格生物医药-B股票交易,派格生物医药-B股票购买,派格生物医药-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"派格生物医药-B(02565)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供派格生物医药-B(02565)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}